Cargando…

The Fourth Dose of mRNA COVID-19 Vaccine Following 12 Different Three-Dose Regimens: Safety and Immunogenicity to Omicron BA.4/BA.5

The aim of this study is to investigate the reactogenicity and immunogenicity of the fourth dose using monovalent mRNA vaccines after different three-dose regimens and to compare the 30 µg BNT162b2 and 50 µg mRNA-1273 vaccines. This prospective cohort study was conducted between June and October 202...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kanokudom, Sitthichai, Chansaenroj, Jira, Suntronwong, Nungruthai, Assawakosri, Suvichada, Yorsaeng, Ritthideach, Nilyanimit, Pornjarim, Aeemjinda, Ratchadawan, Khanarat, Nongkanok, Vichaiwattana, Preeyaporn, Klinfueng, Sirapa, Thongmee, Thanunrat, Srimuan, Donchida, Thatsanathorn, Thaksaporn, Sudhinaraset, Natthinee, Wanlapakorn, Nasamon, Honsawek, Sittisak, Poovorawan, Yong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10053821/ https://www.ncbi.nlm.nih.gov/pubmed/36992154 http://dx.doi.org/10.3390/vaccines11030570

Ejemplares similares

SARS-CoV-2 Antibody Dynamics after COVID-19 Vaccination and Infection: A Real-World Cross-Sectional Analysis
por: Yorsaeng, Ritthideach, et al.
Publicado: (2023)

Safety and immunogenicity of a third dose of COVID-19 protein subunit vaccine (Covovax(TM)) after homologous and heterologous two-dose regimens
por: Kanokudom, Sitthichai, et al.
Publicado: (2023)

Immunogenicity Following Two Doses of the BBIBP-CorV Vaccine and a Third Booster Dose with a Viral Vector and mRNA COVID-19 Vaccines against Delta and Omicron Variants in Prime Immunized Adults with Two Doses of the BBIBP-CorV Vaccine
por: Chansaenroj, Jira, et al.
Publicado: (2022)

Safety and Immunogenicity of the Third Booster Dose with Inactivated, Viral Vector, and mRNA COVID-19 Vaccines in Fully Immunized Healthy Adults with Inactivated Vaccine
por: Kanokudom, Sitthichai, et al.
Publicado: (2022)

Strong Correlations between the Binding Antibodies against Wild-Type and Neutralizing Antibodies against Omicron BA.1 and BA.2 Variants of SARS-CoV-2 in Individuals Following Booster (Third-Dose) Vaccination
por: Suntronwong, Nungruthai, et al.
Publicado: (2022)

Seroprevalence of SARS-CoV-2 anti-nucleocapsid total Ig, anti-RBD IgG antibodies, and infection in Thailand: a cross-sectional survey from October 2022 to January 2023
por: Chansaenroj, Jira, et al.
Publicado: (2023)

Persistence of immunity against Omicron BA.1 and BA.2 variants following homologous and heterologous COVID-19 booster vaccines in healthy adults after a two-dose AZD1222 vaccination
por: Assawakosri, Suvichada, et al.
Publicado: (2022)

Real-World Study: Hybrid Immunity against SARS-CoV-2 Influences the Antibody Levels and Persistency Lasting More than One Year
por: Kanokudom, Sitthichai, et al.
Publicado: (2023)

Comparison of the reactogenicity and immunogenicity of a reduced and standard booster dose of the mRNA COVID-19 vaccine in healthy adults after two doses of inactivated vaccine
por: Kanokudom, Sitthichai, et al.
Publicado: (2022)

Immunogenicity of a third dose viral-vectored COVID-19 vaccine after receiving two-dose inactivated vaccines in healthy adults
por: Yorsaeng, Ritthideach, et al.
Publicado: (2022)

COVID-19 Breakthrough Infection after Inactivated Vaccine Induced Robust Antibody Responses and Cross-Neutralization of SARS-CoV-2 Variants, but Less Immunity against Omicron
por: Suntronwong, Nungruthai, et al.
Publicado: (2022)

Safety and immunogenicity of heterologous and homologous inactivated and adenoviral-vectored COVID-19 vaccine regimens in healthy adults: a prospective cohort study
por: Wanlapakorn, Nasamon, et al.
Publicado: (2022)

SARS-CoV-2 infection- induced seroprevalence among children and associated risk factors during the pre- and omicron-dominant wave, from January 2021 through December 2022, Thailand: A longitudinal study
por: Suntronwong, Nungruthai, et al.
Publicado: (2023)

Evaluation of Anti-S1 IgA Response to Different COVID-19 Vaccination Regimens
por: Bureerug, Teeraporn C., et al.
Publicado: (2023)

Immunogenicity of heterologous inactivated and adenoviral-vectored COVID-19 vaccine: Real-world data
por: Wanlapakorn, Nasamon, et al.
Publicado: (2022)

Dynamics of Cytokine, SARS-CoV-2-Specific IgG, and Neutralizing Antibody Levels in COVID-19 Patients Treated with Convalescent Plasma
por: Pratedrat, Pornpitra, et al.
Publicado: (2023)

Climate factors influence seasonal influenza activity in Bangkok, Thailand
por: Suntronwong, Nungruthai, et al.
Publicado: (2020)

Characterizing genetic and antigenic divergence from vaccine strain of influenza A and B viruses circulating in Thailand, 2017–2020
por: Suntronwong, Nungruthai, et al.
Publicado: (2021)

Prevalence of antibodies against seasonal influenza A and B viruses among older adults in rural Thailand: A cross-sectional study
por: Suntronwong, Nungruthai, et al.
Publicado: (2021)

Genetic and antigenic divergence in the influenza A(H3N2) virus circulating between 2016 and 2017 in Thailand
por: Suntronwong, Nungruthai, et al.
Publicado: (2017)

Evolution of the neuraminidase gene of seasonal influenza A and B viruses in Thailand between 2010 and 2015
por: Tewawong, Nipaporn, et al.
Publicado: (2017)

Evolutionary and Genetic Recombination Analyses of Coxsackievirus A6 Variants Associated with Hand, Foot, and Mouth Disease Outbreaks in Thailand between 2019 and 2022
por: Puenpa, Jiratchaya, et al.
Publicado: (2022)

Safety and Humoral and Cellular Immunogenicity of the BNT162b2 SARS-CoV-2 Vaccine in Liver-Transplanted Adolescents Compared to Healthy Adolescents
por: Sintusek, Palittiya, et al.
Publicado: (2022)

Epidemiology and clinical characteristics of severe acute respiratory infections among hospitalized children under 5 years of age in a tertiary care center in Bangkok, Thailand, 2019–2020
por: Wanlapakorn, Nasamon, et al.
Publicado: (2023)

Molecular epidemiology of the first wave of severe acute respiratory syndrome coronavirus 2 infection in Thailand in 2020
por: Puenpa, Jiratchaya, et al.
Publicado: (2020)

Detection of SARS-CoV-2-specific antibodies via rapid diagnostic immunoassays in COVID-19 patients
por: Chansaenroj, Jira, et al.
Publicado: (2021)

The impact of COVID-19 and control measures on public health in Thailand, 2020
por: Yorsaeng, Ritthideach, et al.
Publicado: (2022)

Assessing Antigenic Drift of Seasonal Influenza A(H3N2) and A(H1N1)pdm09 Viruses
por: Tewawong, Nipaporn, et al.
Publicado: (2015)

Dynamic Antibody Response and Hybrid Immunity Following Multiple COVID-19 Vaccine Doses and Infection: A Case Study
por: Kanokudom, Sitthichai, et al.
Publicado: (2023)

Comparison of human papillomavirus (HPV) detection in urine and cervical swab samples using the HPV GenoArray Diagnostic assay
por: Nilyanimit, Pornjarim, et al.
Publicado: (2017)

Comparison of Four Human Papillomavirus Genotyping Methods: Next-generation Sequencing, INNO-LiPA, Electrochemical DNA Chip, and Nested-PCR
por: Nilyanimit, Pornjarim, et al.
Publicado: (2018)

Respiratory syncytial virus, human metapneumovirus, and influenza virus infection in Bangkok, 2016-2017
por: Thongpan, Ilada, et al.
Publicado: (2019)

Seroprevalence of Antibodies to Pertussis Toxin among Different Age Groups in Thailand after 37 Years of Universal Whole-Cell Pertussis Vaccination
por: Wanlapakorn, Nasamon, et al.
Publicado: (2016)

Antibodies to Bordetella pertussis antigens in maternal and cord blood pairs: a Thai cohort study
por: Wanlapakorn, Nasamon, et al.
Publicado: (2017)

To BaP or not to BaP? That is the question.
por: Goldstein, L S
Publicado: (2001)

Neutralization of Omicron BA.4/BA.5 and BA.2.75 by booster vaccination or BA.2 breakthrough infection sera
por: Wang, Xun, et al.
Publicado: (2022)

Omicron BA.2 breakthrough infection enhances cross-neutralization of BA.2.12.1 and BA.4/BA.5
por: Muik, Alexander, et al.
Publicado: (2022)

Large-scale outbreak of Chikungunya virus infection in Thailand, 2018–2019
por: Khongwichit, Sarawut, et al.
Publicado: (2021)

Omicron Waves in Argentina: Dynamics of SARS-CoV-2 Lineages BA.1, BA.2 and the Emerging BA.2.12.1 and BA.4/BA.5
por: Torres, Carolina, et al.
Publicado: (2023)

Safety and Efficacy of a Third Dose of the BNT162b2 Vaccine in Liver-Transplanted and Healthy Adolescents
por: Sintusek, Palittiya, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_3eff6sbfue784a32rvlrb3j622